PetMed Express, Inc. Q4 FY2026 earnings call

- **Regulatory & Compliance Progress**: The company regained critical regulatory compliance by completing all delayed SEC filings (fiscal 2025 Form 10-K in October 2025, fiscal 2026 Q1 and Q2 filings in December 2025), changed external auditors to Baker Tilly US LLP, held its delayed 2025 annual shareholder meeting in January 2026, and fully remediated three previously disclosed material weaknesses in internal controls: tone at the top, complex accounting issues, and income taxes. - **Financial Performance & Cost Optimization**: Full year 2026 net sales declined 21.1% year-over-year to $179 million, while Q4 2026 net sales declined 15.6% year-over-year to $42.8 million (17.8% adjusted for the New York sales tax settlement), showing a slowing decline rate. Q4 2026 delivered the first sequential quarterly net sales increase for Q4 since fiscal 2024. Non-recurring items in full year 2026 results included a $26.7 million non-cash Q1 goodwill impairment, a $2.1 million Q3 wholesale inventory write-down for an unsuccessful non-core initiative, and $4.5 million in non-recurring legal, professional, and executive severance costs related to a prior whistleblower investigation. Cost reduction efforts exited underperforming vendor relationships, generating $6.1 million in annualized savings, and general and administrative expenses declined 8.6% year-over-year in Q4 2026 to $11.4 million. The New York state sales tax liability was settled in Q4, reducing full year 2026 net loss by $2.8 million. Gross margin improved 270 basis points year-over-year to 32.6% in Q4 2026, driven primarily by the tax settlement. - **Operational & Technology Improvements**: The company strategically reorganized headcount across pharmacy, call center, and distribution centers to align costs with business size, improve productivity, and enhance customer experience, with customer-facing operational metrics showing significant improvement year-over-year. Major technology and infrastructure modernization projects were completed, including implementation of a new ERP system, new fraud prevention system, and new call center phone system technology, creating a modernized tech backbone to support operations. Going forward, the company will prioritize website and user experience optimization and reduced operational risk. - **Leadership, Cultural & Strategic Updates**: The company celebrated its 30th anniversary in January 2026, with over 40 long-tenured employees (more than 10 years of service, half expected to hit 20 years by end of 2026). The leadership structure was reorganized to add a Chief Growth Officer role aligning marketing, buying, and merchandising, with multiple key internal promotions across operations demonstrating internal talent depth. Employee benefits were expanded, and employee satisfaction ratings increased substantially. The company is pursuing growth through improved customer retention and new B2B expansion, including white label pharmacy fulfillment, with a recently announced master services agreement with Rural Kings. The board evaluated two unsolicited non-binding preliminary acquisition proposals received in December 2025, priced at $4 to $4.25 per share, and determined it would not proceed with either, so the company will remain independent, though the board remains open to evaluating future inbound proposals in line with fiduciary duties.

The transcript does not break out financial performance for distinct product segments in absolute terms or revenue contribution percentages. It notes that overall net sales declines in both Q4 2026 and full fiscal 2026 were primarily driven by a decline in prescription medication sales, and identifies prescription medication, non-prescription food, and auto-ship as core business lines that showed early positive momentum in the second half of fiscal 2026.

Management did not provide specific numerical forward guidance or explicit upward/downward revisions to prior guidance in this call. Management stated that the financial, operational, technological, and cultural improvements completed in fiscal 2026 create a strong foundation for long-term performance as the company enters fiscal 2027, and that the company is positioned to focus on disciplined execution of strategic priorities to deliver shareholder value.

- Forward-looking statements on the call are inherently uncertain, and actual results could differ materially from projections due to unstated risks and assumptions, consistent with disclosures in the company's SEC filings including the most recent Form 10-K. - The company faced material challenges, including revenue declines and internal control weaknesses, in prior periods, though meaningful progress has been made to remediate issues and stabilize the core business. - The company's early positive momentum from recent strategic initiatives is described as modest, and there is no guarantee these initiatives will deliver sustained long-term growth or improved financial results.

There were no questions asked or answered during the published portion of this conference call.